Loading...

LNTH LANTHEUS HOLDINGS INC Capital Structure Changes 8-K Filing

LNTH

LNTH

LANTHEUS HOLDINGS INC

(LNTH)

2025 8-K

Financial Results Report

Shareholder Approvals

Financial Results Update

CEO Retirement Announcement

Leadership Transition

Asset Acquisitions

Financial Statements

Amendments to Articles of I...

Acquisition Completed

Financial Results

Board Appointment

Merger Agreement

Acquisition Agreement

Credit Agreement Amendment

Management Change

Share Buyback Program

Q3 2024 Results

SPLASH Trial Update

Financial Results Announcement

Acquisition Announcement

Appointment of Chief Accoun...

Departure of Chief Medical ...

Financial Results Announcement

Amendment to Equity Incenti...

Financial Results Announcement

Lawsuit for Patent Infringe...

Management Changes

Financial Results Announcement

Financial Results Announcement

Discontinuation of AZEDRA P...

Financial Results and Royal...

Lease Amendment

Financial Results Announcement

Annual Meeting Approval

Appointment of President

Financial Results Announcement

Acquisition of Cerveau Tech...

Investor Conferences

External Links:

On August 6, 2025, Lantheus Holdings, Inc. reported its financial results for the second quarter of 2025 and announced that the FDA accepted a new drug application for its imaging agent. Additionally, the company authorized a $400 million stock repurchase program to run through December 31, 2027.

AI Assistant

LANTHEUS HOLDINGS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.